Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Molecular and Translational Medicine, University of Brescia, Italy.
Departmen of Physical Therapy, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Mol Genet Metab. 2022 Sep-Oct;137(1-2):26-32. doi: 10.1016/j.ymgme.2022.07.009. Epub 2022 Jul 20.
Beta-propeller protein-associated neurodegeneration (BPAN) is a rare neurodegenerative disorder characterized by iron accumulation in the brain with spectrum of neurodevelopmental and movement phenotypes. In anticipation of future clinical trials and to inform clinical care, there is an unmet need to capture the phenotypic diversity of this rare disorder and better define disease subtypes.
A total of 27 individuals with BPAN were included in our natural history study, from which traditional outcome measures were obtained in 18 subjects. Demographic and diagnostic information, along with acquisition of basic developmental skills and overall neurologic severity were extracted from the medical records. Functional outcome measures were administered at the time of the evaluation or applied retrospectively at the last clinical encounter for patients who were not able to travel for in person. Based on age and functional level, the following assessments were administered: Leiter-3, Gross Motor Function Measure (GMFM)-66 Item Sets, Vineland-3, and Peabody-2.
Overall, cognitive function was more impaired compared to gross motor function. Onset of symptoms of BPAN within the first 6 months of life was associated with decreased gain of ambulation and gain of spoken language (ambulation: log-rank test p = 0.0015; gain of first word: p = 0.0015). There was no difference in age at seizure onset by age at initial symptom onset (p = 0.8823). Collection of prospective outcome measures was limited by attention and behavior in our patient population, reinforcing the complexity of phenotype assessment and inadequacy of available standardized tests. Overall, gross motor and adaptive behavior assessments were better able to capture the dynamic range of function across the BPAN population than the fine motor and non-verbal cognitive tests. Floor effects were noted across outcome measures in a subset of individuals for cognitive and adaptive behavior tests.
Our data suggest the distinct phenotypes of BPAN: a severe, early onset form and an attenuated form with higher cognitive capabilities. Early age at onset was a key factor in predicting future neurologic impairment.
β 三叶螺旋蛋白相关神经退行性疾病(BPAN)是一种罕见的神经退行性疾病,其特征是脑内铁积累,并伴有神经发育和运动表型谱。为了未来的临床试验,并为临床护理提供信息,我们需要捕捉这种罕见疾病的表型多样性,并更好地定义疾病亚型。
共有 27 名 BPAN 患者纳入我们的自然史研究,其中 18 名患者获得了传统的结局测量。从病历中提取人口统计学和诊断信息,以及基本发育技能的获得和整体神经严重程度。对于无法亲自前来的患者,在评估时或最后一次临床就诊时进行回顾性应用,以获得功能结局测量。根据年龄和功能水平,进行以下评估: Leiter-3、粗大运动功能测量(GMFM)-66 项集、维兰德-3 和 Peabody-2。
总体而言,认知功能较粗大运动功能受损更严重。BPAN 症状在生命的前 6 个月内出现与步行和言语获得的减少有关(步行:对数秩检验 p = 0.0015;第一词获得:p = 0.0015)。首次症状发作时的年龄与癫痫发作开始时的年龄无差异(p = 0.8823)。由于患者人群的注意力和行为问题,前瞻性结局测量的收集受到限制,这也进一步证实了表型评估的复杂性和现有标准化测试的不足。总体而言,粗大运动和适应行为评估比精细运动和非语言认知测试更能捕捉 BPAN 人群的功能动态范围。认知和适应行为测试的一部分个体出现了结果测量的地板效应。
我们的数据表明 BPAN 具有不同的表型:一种严重、早发的形式和一种认知能力较高的较轻的形式。发病年龄早是预测未来神经损伤的关键因素。